Guanylate Binding Protein 3 (GBP3) in Neurodegenerative Diseases, Cancer and Autoimmune Disorders

Target Name: GBP3

NCBI ID: G2635

GBP3

Guanylate Binding Protein 3 (GBP3) in Neurodegenerative Diseases, Cancer and Autoimmune Disorders

Guanylate binding protein 3 (GBP3) is a protein that is expressed in various tissues throughout the body. It plays a crucial role in the regulation of cellular processes, including cell signaling, DNA replication, and apoptosis. GBP3 has also been implicated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it is a potential drug target or biomarker that could be targeted by therapeutic approaches.

Diseases associated with GBP3

GBP3 has been implicated in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most significant findings related to GBP3 is its involvement in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms, including cognitive decline, tremors, and difficulty with daily activities.

GBP3 is a key regulator of the neurotransmitter acetylcholine, which is involved in memory and cognitive function. In neurodegenerative diseases, the levels of acetylcholine in the brain are believed to contribute to the progressive loss of brain cells and the development of symptoms. By inhibiting the activity of GBP3, researchers have found that they can reduce the production of toxic neurotransmitters, such as beta-amyloid, which is a hallmark protein associated with the development of Alzheimer's disease.

Another potential disease associated with GBP3 is cancer. GBP3 has been shown to be involved in the regulation of cell signaling pathways, including the TGF-beta pathway. This pathway is known to play a role in the development and progression of many types of cancer. By inhibiting the activity of GBP3, researchers have found that they can reduce the production of pro-tumorogenic signals, such as TGF-beta2, which can contribute to the development of cancer.

GBP3 and autoimmune disorders

GBP3 has also been implicated in the development and progression of autoimmune disorders. These conditions are characterized by the immune system attacking the body's own tissues, leading to a range of symptoms, including inflammation, autoimmune diseases, and fatigue.

One of the most significant findings related to GBP3 and autoimmune disorders is its involvement in the regulation of the immune response. GBP3 has been shown to be involved in the regulation of the production and function of regulatory T cells, which are a type of immune cell that help to regulate and control the immune response. By modulating the activity of regulatory T cells, GBP3 has been shown to play a role in the development and progression of autoimmune diseases.

Therapeutic applications of GBP3

GBP3 is a potential drug target or biomarker that could be targeted by therapeutic approaches for a range of diseases. One of the most promising approaches for targeting GBP3 is the use of small molecules that can inhibit its activity. Researchers have developed a number of compounds that have been shown to inhibit the activity of GBP3, and these compounds have been shown to be effective in a range of animal models of disease.

One of the most promising compounds is called GF12, which is a small molecule that inhibits the activity of GBP3. GF12 has been shown to be effective in a range of animal models of disease, including neurodegenerative diseases and cancer. Studies have shown that GF12 can reduce the production of beta-amyloid, TGF-beta2, and other pro-tumorogenic signals in a range of cancer cells.

Another compound that has shown promise is called IDH, which is a small molecule that inhibits the activity of GBP3

Protein Name: Guanylate Binding Protein 3

Functions: Interferon (IFN)-inducible GTPase that plays important roles in innate immunity against a diverse range of bacterial, viral and protozoan pathogens (PubMed:22106366). Hydrolyzes GTP very efficiently; GDP rather than GMP is the major reaction product (By similarity). Following infection, recruited to the pathogen-containing vacuoles or vacuole-escaped bacteria and acts as a positive regulator of inflammasome assembly by promoting the release of inflammasome ligands from bacteria (By similarity). Acts by promoting lysis of pathogen-containing vacuoles, releasing pathogens into the cytosol (By similarity). Following pathogen release in the cytosol, promotes recruitment of proteins that mediate bacterial cytolysis: this liberates ligands that are detected by inflammasomes, such as lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11 inflammasome or double-stranded DNA (dsDNA) that activates the AIM2 inflammasome (By similarity). Exhibits antiviral activity against influenza virus (PubMed:22106366)

The "GBP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GBP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets